I came across this podcast on Windlas Biotech
I hope you find it useful.
dr.vikas
I came across this podcast on Windlas Biotech
I hope you find it useful.
dr.vikas
14-15% stake will be holding by Mr. Utpal seth, erstwhile mgr at RARE enterprises …not by RARE ENTERPRISES of Rakesh jhunjhunwala
Please do mention the source of this information.
dr.vikas
Good read with red flag : Windlas Biotech | IPO Analysis | SPTulsian.com
I am sharing an in depth blog on Indian CDMOs
I hope you find it useful
dr.vikas
For existing investors, what is the potential return expectation from the stock? The management has guided for ₹1,000 crore in revenue once the capex is fully operational, along with a 2-3% improvement in margins. In a best-case scenario, the company could achieve a PAT of ₹110 crore with 15% ebidta margins. Based on this, what price-to-earnings (P/E) multiple would be reasonable to attribute to the stock?
You can take the Industry median of around 35x but PAT margin can’t get 15% that would be 10% max, 15% is EBITDA margin guidance